本文關(guān)鍵詞： 整體上市 績(jī)效評(píng)價(jià) 突變級(jí)數(shù)法 熵值法　出處：《深圳大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：2004年,TCL通過換股IPO模式率先在國(guó)內(nèi)實(shí)現(xiàn)了整體上市,自此以后,中國(guó)資本市場(chǎng)上很多企業(yè)集團(tuán)都紛紛開始實(shí)施整體上市,2007年更是達(dá)到了高峰。特別是隨著2015年國(guó)有企業(yè)改革總體方案的發(fā)布,新一輪的國(guó)企改革大幕已經(jīng)拉開。2010年3月,上海醫(yī)藥通過重組實(shí)現(xiàn)整體上市,重組資產(chǎn)量達(dá)到300億元,交易對(duì)價(jià)164億元,這是中國(guó)醫(yī)藥產(chǎn)業(yè)里重組資產(chǎn)量和對(duì)價(jià)最大的一個(gè)案例。本文則以上海醫(yī)藥重組上市為案例進(jìn)行研究,為上海醫(yī)藥整體上市構(gòu)建了綜合績(jī)效評(píng)價(jià)體系。本文首先梳理了整體上市、績(jī)效及其關(guān)聯(lián)關(guān)系的國(guó)內(nèi)外相關(guān)文獻(xiàn),對(duì)國(guó)內(nèi)外關(guān)于該課題的研究現(xiàn)狀進(jìn)行了解;然后對(duì)整體上市和績(jī)效的相關(guān)概念和理論進(jìn)行界定和總結(jié);接著介紹上海醫(yī)藥整體上市的主要過程。在以上文獻(xiàn)綜述和理論的基礎(chǔ)上,為上海醫(yī)藥整體上市構(gòu)建綜合績(jī)效評(píng)級(jí)體系,利用突變級(jí)數(shù)法和熵值法相結(jié)合,從上海醫(yī)藥財(cái)務(wù)績(jī)效、協(xié)同績(jī)效和社會(huì)績(jī)效著手進(jìn)行評(píng)價(jià),并計(jì)算出數(shù)據(jù)進(jìn)行縱向?qū)Ρ?分析上海醫(yī)藥整體上市前后績(jī)效的變化情況。本文運(yùn)用熵值法對(duì)各項(xiàng)指標(biāo)進(jìn)行指標(biāo)權(quán)重的賦予,避免了由人為因素造成的影響,同時(shí)運(yùn)用突變級(jí)數(shù)法對(duì)數(shù)據(jù)進(jìn)行整體分析,將各指標(biāo)聯(lián)系起來整體分析,得到整體績(jī)效的評(píng)價(jià)。同時(shí)引入醫(yī)藥行業(yè)的其他兩大醫(yī)藥企業(yè)的財(cái)務(wù)績(jī)效數(shù)據(jù)與上海醫(yī)藥進(jìn)行橫向?qū)Ρ?分析上海醫(yī)藥整體上市前后財(cái)務(wù)績(jī)效與同行業(yè)的其他兩大醫(yī)藥企業(yè)之間的差距,加強(qiáng)整體上市與財(cái)務(wù)績(jī)效提升之間的關(guān)系。研究結(jié)果表明,整體上市對(duì)上海醫(yī)藥的績(jī)效提升具有正面影響。但從長(zhǎng)期來看,上海醫(yī)藥的協(xié)同績(jī)效方面的數(shù)據(jù)是有所下降的。最后根據(jù)上海醫(yī)藥整體上市績(jī)效的表現(xiàn)及其影響因素為醫(yī)藥企業(yè)整體上市提供建議參考。
[Abstract]:In 2004, TCL took the lead in realizing the overall listing in China through the mode of stock exchange IPO, and since then, In China's capital market, many enterprise groups have begun to implement the overall listing, and reached a peak in 2007. In particular, with the release of the general plan for the reform of state-owned enterprises in 2015, a new round of state-owned enterprise reform has been launched. On March 2010, Shanghai Pharmaceutical listed as a whole through restructuring. The amount of assets reorganized amounted to 30 billion yuan, with a transaction price of 16.4 billion yuan. This is the largest case of recombination assets and consideration in the Chinese pharmaceutical industry. A comprehensive performance evaluation system is constructed for the overall listing of Shanghai medicine. Firstly, this paper reviews the related literature on the whole listing, performance and its correlation relationship, and makes an understanding of the status quo of the research on this subject at home and abroad. Then it defines and summarizes the related concepts and theories of holistic listing and performance, and then introduces the main process of holistic listing of Shanghai medicine. In order to set up a comprehensive performance rating system for the whole listing of Shanghai Medicine, this paper uses the catastrophe series method and entropy method to evaluate the financial performance, synergistic performance and social performance of Shanghai medicine, and calculates the data for longitudinal comparison. This paper analyzes the changes of the performance before and after the overall listing of Shanghai medicine. The entropy method is used to endow each index with the index weight, which avoids the influence caused by human factors. At the same time, the abrupt progression method is used to analyze the data as a whole. The financial performance data of the other two major pharmaceutical enterprises in the pharmaceutical industry are introduced to compare with the Shanghai pharmaceutical industry horizontally. This paper analyzes the gap between the financial performance before and after the overall listing of Shanghai medicine and the other two pharmaceutical enterprises in the same industry, and strengthens the relationship between the overall listing and the improvement of financial performance. The overall listing has a positive impact on the performance of Shanghai Medicine. But in the long run, Finally, according to the performance of the overall listed performance of Shanghai Medicine and its influencing factors, the paper provides some suggestions for the overall listing of pharmaceutical enterprises.
【學(xué)位授予單位】：深圳大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：F832.51;F426.72;F406.7

【參考文獻(xiàn)】

相關(guān)期刊論文 前8條

1 尹開國(guó);劉小芹;;公司社會(huì)績(jī)效與財(cái)務(wù)績(jī)效關(guān)系研究[J];財(cái)會(huì)通訊;2014年33期

2 韓新華;馬春愛;;熵值賦權(quán)的改進(jìn)思路探討[J];會(huì)計(jì)之友;2013年31期

3 徐志培;;鹽業(yè)集團(tuán)整體上市動(dòng)因研究[J];現(xiàn)代商業(yè);2013年18期

4 王長(zhǎng)禹;;基于熵值法的醫(yī)院臨床科室財(cái)務(wù)績(jī)效評(píng)價(jià)研究[J];會(huì)計(jì)之友;2013年16期

5 耿建新;林春雷;;上市公司收購境內(nèi)企業(yè)外資股權(quán)的財(cái)務(wù)績(jī)效研究[J];南京審計(jì)學(xué)院學(xué)報(bào);2012年01期

6 張安榕;;后股權(quán)分置時(shí)代我國(guó)集團(tuán)公司整體上市的動(dòng)因、模式與特點(diǎn)分析[J];科技廣場(chǎng);2011年02期

7 常小兵;;我國(guó)企業(yè)管理中的協(xié)同效應(yīng)研究[J];企業(yè)研究;2010年05期

8 朱琪,黃祖輝;我國(guó)上市公司并購中控制權(quán)變更市場(chǎng)效應(yīng)的實(shí)證研究[J];中國(guó)管理科學(xué);2004年03期

，

本文編號(hào)：1507013